Chinese exoskeleton firms are turning advanced technology into practical daily products.

Founded in 2017, Hangzhou‑based RoboCT focuses on medical rehabilitation exoskeletons. It independently developed core components over five years and obtained official approval in 2022.

Its products are used in over 1,000 Chinese medical institutions, and the company helped set industry standards. New brain‑computer interface‑integrated models have entered clinical trials.

Another startup, Hypershell, targets daily‑use exoskeletons.

After canceling its first generation, it launched a lighter second‑generation device under 2kg with AI motion control.

Priced like a high‑end smartphone, its products are sold in over 70 countries, suitable for hiking, commuting and rescue.

Both firms see exoskeletons becoming lighter, smarter and more integrated into daily life.